DENVER, March 8, 2007 -- Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP) a biopharmaceutical company focused on infectious disease and dermatology, today announced that it will conduct a live webcast to present data on the use of Ceragenins to prevent bacterial colonization of medical devices as well as its ability to virtually eradicate bacteria and fungi as a contact lens disinfectant.
The webcast will provide highlights from recent presentations given by Dr. Paul B. Savage, the Reed M. Izatt Professor of Chemistry and Biochemistry at Brigham Young University (BYU), to the scientific community. Dr. Savage is the inventor of the Ceragenin technology which Ceragenix has exclusively licensed from Brigham Young University. Following the presentation, Dr. Savage and company management will be available to take questions. The presentation will be moderated by Edward H. Nash, Stifel Nicolaus & Company's equity research analyst for biotechnology and life sciences.
Date & Time: March 12, 2007 @ 1:00 PM Eastern Time Webcast link for viewing presentation: http://www.vcall.com/IC/CEPage.asp?ID=114215 Participant Dial in: U.S. and Canada (Toll Free): 877-407-0782 Participant Dial in: International: 201-689-8567 The call will be available for replay at http://www.investorcalendar.com/ClientPage.asp?ID=114215 or http://www.investorcalendar.com/ Replay Number for U.S. and Canada (Toll Free): 877-660-6853 Replay Number for International: 201-612-7415 Account # 286 Conference ID #: 232309
About Ceragenix
Ceragenix Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops and commercializes novel anti-infective drugs based on its proprietary class of compounds, Ceragenins (or CSAs). Active against a broad range of gram positive and negative bacteria, these agents are being developed as anti-infective medical device coatings and as therapeutics for antibiotic-resistant organisms. Ceragenix also owns exclusive rights to Barrier Repair Technology for the treatment of dermatological disorders including atopic dermatitis, neonatal skin disorders and others. Ceragenix's patented Barrier Repair Technology, invented by Dr. Peter Elias and licensed from the University of California, is the platform for the development of two prescription topical creams--EpiCeram(TM) and NeoCeram(TM). For additional information on Ceragenix, please visit www.ceragenix.com.